Management of Atrial Fibrillation Suppression in AF-HF Comorbidity Therapy (MASCOT) Trial
Inter- [1,2], intra- [3,4], and atrioventricular [51(AV) dyssynchrony are not new concepts, but only recently have attempts been made to correct these disorders in an effort to treat heart failure (HF). A series of trials  has addressed partial or comprehensive cardiac resynchronization in patients with severe HF and evidence of cardiac dyssynchrony. Cardiac resynchronization should improve left ventricular (LV) performance; several trials [7-10] have demonstrated improvement in many hemodynamic parameters (LV and aortic pressure, shortening of mitral diastolic regurgitation, synchronized LV and atrial systole, LV volume, reduced myocardial oxygen consumption) and clinical end-points (quality of life, peak oxygen uptake, functional capacity, reduced number of hospitalizations). The incidence of atrial fibrillation (AF) double every 10 years in adults: there are 2-3 new cases/1000 annually in the age group of 55-64 years and 35 new cases/1000 annually between the age of 85 and 94 years [11-13]. The Framingham study demonstrated that AF is an independent risk factor for mortality with a relative risk of 1.5 for men and 1.9 for women. In patients with HF, the prevalence of AF is directly related to NYHA class: AF is present in 10% of patients in NYHA class II and 40% of patients in NYHA classes III-IV. However, HF morbidity is highly influenced by the coexistence of AF, independently of functional class. Moreover, the presence of symptomatic or asymptomatic AF in patients with LV dysfunction is linked to a poor prognosis and is independently associated with a higher risk of death from all causes and from progressive pump failure [14,15]. The prevalence of AF in most trials [16-22] on HF is shown in Fig. 1.
KeywordsAtrial Fibrillation NYHA Class Atrial Systole Asymptomatic Atrial Fibrillation Cardiac Dyssynchrony
Unable to display preview. Download preview PDF.
- 1.Wolferth CC, Margolies A (1935) Asynchronism in contraction of the ventricles in the so-called common type of bundle-branch block: its bearing on the determination of the side of the significant lesion and on the mechanism of split first and second heart sound. Am Heart J 10:425–452CrossRefGoogle Scholar
- 8.Louis A, Cleland JGF, Crabbe S et al (2001) Clinical trials update. CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2. RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology 2001. Eur J Heart Fail 3:381–387PubMedCrossRefGoogle Scholar
- 9.Thackray S, Coletta A, Jones P, Dunn A, Clark AL, Cleland JGF (2001) Clinical trials update. Highlights of the scientific session of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK CD, CHRISTMAS, OPTIME-CHF. Eur J Heart Fail 3:491–494PubMedCrossRefGoogle Scholar
- 10.Auricchio A, Stellbrink C, Sack S et al (1998) The pacing therapies for congestive heart failure (PATH-CHF) study. Circulation 102 [Suppl 2]:693 (abstract 3352)Google Scholar
- 18.Pedersen OD, Bagger H, Keller N et al (2001) Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy. Circulation 104: 292–296PubMedCrossRefGoogle Scholar
- 19.Deedwania PC, Singh BN, Ellenbogen KA et al (1998) Spontaneous conversion and mantainance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observation from the Veterans Congestive Heart Failure Trial on Antiarrhythmic Therapy (CHF-STAT). Circulation 98:2574–2579PubMedCrossRefGoogle Scholar
- 20.Carson PE, Johnson DR, Dunkman WB et al (1993) The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. Circulation Suppl VI:VI102–110Google Scholar
- 21.Dries DL, Exner DV, Gersh BJ et al (1998) Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD Trials. J Am Coll Cardiol 32:695–703PubMedCrossRefGoogle Scholar